Yue-Li Sun

TL;DR: Evidence is provided that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti-PD-1/PD-L1 immunotherapy.

TL;DR: Favorable responses were observed in patients with G719X and compound L858R mutations, indicating that they may benefit from EGFR-TKIs as a first-line therapy, suggests this retrospective study reviews the prevalence of uncommon EGFR mutations in a Chinese NSCLC cohort.

TL;DR: Patients with solid predominant LUAD may represent a potential selective group that will benefit from adjuvant programmed cell death 1 blockade immunotherapy, and was identified as a subtype with adaptive immune resistance, higher cytotoxic activity, and enhanced immunogenicity.

TL;DR: Evaluating the clinical characteristics and molecular profile of ROS1-rearranged patients with non-small-cell lung cancer (NSCLC) and correlated ROS1 rearrangement status with clinical features concluded that patients seem to benefit from crizotinib treatment.